3-(4'-butylbiphenyl-4-yl)propyl methanesulfonate | 1046816-86-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4'-butylbiphenyl-4-yl)propyl methanesulfonate
• 英文别名: 3-[4-(4-Butylphenyl)phenyl]propyl methanesulfonate
• CAS: 1046816-86-7
• 化学式: C₂₀H₂₆O₃S
• 分子量: 346.491
• InChiKey: XIPKGZYOQYKSLQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  24
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4'-butylbiphenyl-4-yl)propyl methanesulfonate 在 sodium iodide 作用下， 以 丙酮 为溶剂， 反应 1.0h， 生成 4'-Butyl[1,1'-biphenyl]-4-propyl iodide
  参考文献：
  名称：

  Phosphonosulfonates Are Potent, Selective Inhibitors of Dehydrosqualene Synthase and Staphyloxanthin Biosynthesis in Staphylococcus aureus

  摘要：

  Staphylococcus aureus produces a golden carotenoid virulence factor called staphyloxanthin (STX), and we report here the inhibition of the enzyme, dehydrosqualene synthase (CrtM), responsible for the first committed step in STX biosynthesis. The most active compounds are halogen-substituted phosphonosulfonates, with K-i values as low as 5 nM against the enzyme and IC50 values for STX inhibition in S. aureus as low as 11 nM. There is, however, only a poor correlation (R-2 = 0.27) between enzyme and cell pIC(50) (= -log(10) IC50) values. The ability to predict cell from enzyme data improves considerably (to R-2 = 0.72) with addition of two more descriptors. We also investigated the activity of these compounds against human squalene synthase (SQS), as a counterscreen, finding several potent STX biosynthesis inhibitors with essentially no squalene synthase activity. These results open up the way to developing potent and selective inhibitors of an important virulence factor in S. aureus, a major human pathogen.

  DOI：

  10.1021/jm801023u
• 作为产物：
  描述：

  4'-Butyl[1,1'-biphenyl]-4-propanol 、 甲基磺酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 3-(4'-butylbiphenyl-4-yl)propyl methanesulfonate
  参考文献：
  名称：

  Phosphonosulfonates Are Potent, Selective Inhibitors of Dehydrosqualene Synthase and Staphyloxanthin Biosynthesis in Staphylococcus aureus

  摘要：

  Staphylococcus aureus produces a golden carotenoid virulence factor called staphyloxanthin (STX), and we report here the inhibition of the enzyme, dehydrosqualene synthase (CrtM), responsible for the first committed step in STX biosynthesis. The most active compounds are halogen-substituted phosphonosulfonates, with K-i values as low as 5 nM against the enzyme and IC50 values for STX inhibition in S. aureus as low as 11 nM. There is, however, only a poor correlation (R-2 = 0.27) between enzyme and cell pIC(50) (= -log(10) IC50) values. The ability to predict cell from enzyme data improves considerably (to R-2 = 0.72) with addition of two more descriptors. We also investigated the activity of these compounds against human squalene synthase (SQS), as a counterscreen, finding several potent STX biosynthesis inhibitors with essentially no squalene synthase activity. These results open up the way to developing potent and selective inhibitors of an important virulence factor in S. aureus, a major human pathogen.

  DOI：

  10.1021/jm801023u

文献信息

• COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY
  申请人：Alper Phillip B.

  公开号：US20100022515A1

  公开（公告）日：2010-01-28

  The invention provides compounds, pharmaceutical compositions comprising compound of following formula (I), and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119 (G protein-coupled receptor 119) such as obesity, diabetes and hyperlipidemia.

  本发明提供了以下式子(I)的化合物、含有该化合物的制药组合物，以及使用这些化合物治疗或预防与GPR119(G蛋白偶联受体119)活性相关的疾病或症状的方法，例如肥胖症、糖尿病和高脂血症。
• [EN] COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS TELS QUE DES MODULATEURS D'UNE ACTIVITÉ GPR119
  申请人：IRM LLC

  公开号：WO2008097428A2

  公开（公告）日：2008-08-14

  [EN] The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.
  [FR] La présente invention concerne des composés, des compositions pharmaceutiques comprenant de tels composés et de tels procédés consistant à utiliser de tels composés pour traiter ou empêcher des maladies ou des troubles associés à l'activité de GPR119.